NED TALK 2021: Managing BTK Inhibitor–Related Adverse Events and Improving Adherence

NED TALK 2021: Managing BTK Inhibitor–Related Adverse Events and Improving Adherence

Saturday, June 12, 2021
Webinar -- 3:30 PM ET


  • Overview of currently available BTK inhibitors, including current indications and impact on patient outcomes
  • Overview of common and serious AEs that emerge during BTK inhibitors therapy and available management options
  • Understand and managing BTK inhibitor–associated cardiac AEs
  • Considerations regarding drug–food interactions and drug–drug interactions
  • Patient education: how they will access and receive their BTK inhibitor therapy, tracking adherence, and understanding potential AEs and what to do


Program Director
Beth Faiman, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Amy Goodrich, NP

Research Associate/Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and oncology nurses to optimally care for patients with B-cell malignancies being treated with a BTK inhibitor. 

Target Audience
This educational program is intended for oncology nurses and physician assistants specializing in hematology/oncology involved in the care of patients with B-cell malignancies being treated with a BTK inhibitor.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Provide patient-focused education on the most common and serious AEs associated with BTK inhibitor monotherapy and combination treatment
  • Develop a proactive management plan for AEs associated BTK inhibitor therapy to support quality of life and continuation of treatment
  • Manage the physical, emotional, and social challenges experienced by patients diagnosed with MCL, MZL, CLL/SLL, and WM undergoing treatment with BTK inhibitor therapy
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.